• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.

作者信息

Bewersdorf Jan Philipp, Giri Smith, Wang Rong, Williams Robert T, Tallman Martin S, Zeidan Amer M, Stahl Maximilian

机构信息

Yale University.

Division of Hematology and Oncology, University of Alabama School of Medicine.

出版信息

Haematologica. 2020 Nov 1;105(11):2659-2663. doi: 10.3324/haematol.2019.242826.

DOI:10.3324/haematol.2019.242826
PMID:33131256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7604631/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/7604631/a2bc4414b541/1052659.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/7604631/c465a3ecf277/1052659.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/7604631/a2bc4414b541/1052659.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/7604631/c465a3ecf277/1052659.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/7604631/a2bc4414b541/1052659.fig2.jpg

相似文献

1
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.维奈托克单药治疗以及联合去甲基化药物或低剂量阿糖胞苷用于复发和难治性急性髓系白血病的系统评价和荟萃分析
Haematologica. 2020 Nov 1;105(11):2659-2663. doi: 10.3324/haematol.2019.242826.
2
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?维奈托克联合去甲基化药物或小剂量阿糖胞苷治疗急性髓系白血病：闪光的都是金子吗？
Blood Cancer J. 2020 Jan 28;10(1):10. doi: 10.1038/s41408-020-0281-x.
3
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.克拉屈滨加阿糖胞苷加维奈克拉治疗对维奈克拉加去甲基化药物难治或复发的急性髓系白血病
Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.
4
Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.孕期难治性急性髓系白血病采用维奈克拉、大剂量阿糖胞苷和米托蒽醌治疗。
Br J Haematol. 2021 Jan;192(2):e60-e63. doi: 10.1111/bjh.17220. Epub 2020 Nov 21.
5
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.维奈克拉联合阿糖胞苷和/或伊达比星治疗复发/难治性儿童急性髓系白血病的 1 期、剂量递增研究。
Lancet Oncol. 2020 Apr;21(4):551-560. doi: 10.1016/S1470-2045(20)30060-7. Epub 2020 Mar 11.
6
Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.基于 venetoclax 的联合疗法治疗未经治疗的急性髓系白血病的疗效和安全性：一项荟萃分析。
Hematology. 2024 Dec;29(1):2343604. doi: 10.1080/16078454.2024.2343604. Epub 2024 May 4.
7
Venetoclax-based therapies for acute myeloid leukemia.基于 Venetoclax 的急性髓系白血病疗法。
Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. doi: 10.1016/j.beha.2019.05.008. Epub 2019 May 24.
8
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.维奈克拉联合低剂量去甲基化药物或阿糖胞苷治疗复发/难治性急性髓系白血病。
Leuk Lymphoma. 2022 Jul;63(7):1645-1650. doi: 10.1080/10428194.2022.2042688. Epub 2022 Mar 8.
9
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.老年急性髓系白血病患者的更多选择：维奈克拉联合小剂量阿糖胞苷。
Chin Clin Oncol. 2019 Oct;8(S1):S25. doi: 10.21037/cco.2019.09.03.
10
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.新型低甲基化剂NTX-301作为单一疗法及与维奈托克联合用于急性髓系白血病的临床前疗效
Blood Cancer J. 2022 Apr 11;12(4):57. doi: 10.1038/s41408-022-00664-y.

引用本文的文献

1
Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia.在成人急性髓系白血病中，使用去甲基化药物和维奈托克后进行强化化疗。
Blood Neoplasia. 2024 Aug 28;1(4):100038. doi: 10.1016/j.bneo.2024.100038. eCollection 2024 Dec.
2
Novel insights and therapeutic approaches in secondary AML.继发性急性髓系白血病的新见解与治疗方法
Front Oncol. 2024 Jul 29;14:1400461. doi: 10.3389/fonc.2024.1400461. eCollection 2024.
3
Efficacy of venetoclax and rituximab in the treatment of concurrent acute myeloid leukemia and untreated chronic lymphocytic leukemia: A case report and literature review.
维奈托克与利妥昔单抗联合治疗同时合并急性髓系白血病和未经治疗的慢性淋巴细胞白血病的疗效：一例病例报告及文献综述
Oncol Lett. 2024 Jun 25;28(2):393. doi: 10.3892/ol.2024.14526. eCollection 2024 Aug.
4
Meta‑analysis of the efficacy of venetoclax and azacitidine combination therapy and azacitidine monotherapy for treating acute myeloid leukemia.维奈克拉与阿扎胞苷联合疗法及阿扎胞苷单药疗法治疗急性髓系白血病疗效的Meta分析
Exp Ther Med. 2024 Feb 26;27(4):164. doi: 10.3892/etm.2024.12452. eCollection 2024 Apr.
5
Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs. Venetoclax 治疗血液系统恶性肿瘤的感染性不良事件风险：RCT 的系统评价和荟萃分析。
Blood Adv. 2024 Feb 27;8(4):857-866. doi: 10.1182/bloodadvances.2023011964.
6
Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial.维奈克拉联合低甲基化药物和 CAG 方案治疗复发/难治性急性髓系白血病：一项单中心临床试验。
Front Immunol. 2023 Nov 20;14:1269163. doi: 10.3389/fimmu.2023.1269163. eCollection 2023.
7
Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.在一项1b/2期研究中，针对复发或难治性急性髓系白血病患者，将PLK1抑制剂onvansertib与地西他滨联合使用，结果发现剪接体突变与临床反应相关。
Ann Hematol. 2023 Nov;102(11):3049-3059. doi: 10.1007/s00277-023-05442-9. Epub 2023 Sep 13.
8
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.维奈克拉联合阿扎胞苷和高三尖杉酯碱治疗复发/难治性急性髓系白血病：一项多中心、2 期临床试验。
J Hematol Oncol. 2023 Apr 29;16(1):42. doi: 10.1186/s13045-023-01437-1.
9
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Venetoclax 和 alvocidib 治疗复发/难治性急性髓系白血病患者的 1b 期研究。
Hematol Oncol. 2023 Oct;41(4):743-752. doi: 10.1002/hon.3159. Epub 2023 Apr 22.
10
Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia.基于维奈克拉方案治疗急性髓系白血病的真实单中心经验。
Front Oncol. 2023 Mar 27;13:1149298. doi: 10.3389/fonc.2023.1149298. eCollection 2023.